FDA Aug. 21 unveiled a major new initiative to revise the agency's current good manufacturing practices program for human and animal drugs, including human biological products. FDA plans to focus its regulatory attention on high-risk areas, provide more flexibility to avoid impeding innovation, and make the cGMP program more consistent across the centers.